Laser, Anti-VEGF Therapy Similar for DME
(MedPage Today) -- Ranibizumab advantage at 2 years lost at 5 (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 25, 2018 Category: Primary Care Source Type: news
Genentech touts positive data for tiny, refillable eye implant
Roche‘s (OTC:RHHBY) Genentech touted positive top-line data today from a Phase II study of its Port Delivery System, an eye implant designed to administer a sustained dose of ranibizumab in patients with wet age-related macular degeneration.
The refillable device, which is roughly the size of a grain of rice, is intended to enable wet-AMD patients to go for months without needing to see an ophthalmologist for treatment. The current standard of care for wet-AMD involves monthly injections of anti-vascular endothelial growth factor therapy.
Get the full story at our sister site, Drug Delivery Business News.
T...
Source: Mass Device - July 25, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat Genentech Roche Source Type: news
Invitation to Roche's Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 2 August 2018, featuring data from the Phase 2 LADDER study of the Port Delivery System (RPDS) with Lucentis to be presented at the American Society of Retina Specialists (ASRS) annual meeting (20-25 July 2018) in Vancouver, Canada. (Source: Roche Investor Update)
Source: Roche Investor Update - July 11, 2018 Category: Pharmaceuticals Source Type: news
FDA approves Lucentis (ranibizumab injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy
Roche today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis ® (ranibizumab injection) 0.3 mg prefilled syringe (PFS) as a new method of administering the medicine to treat all forms of diabetic retinopathy. (Source: Roche Investor Update)
Source: Roche Investor Update - March 22, 2018 Category: Pharmaceuticals Source Type: news
Genentech ’ s pre-filled syringe for diabetic retinopathy wins FDA nod
Roche‘s (OTC:RHHBY) Genentech announced today that the FDA approved its 0.3-mg pre-filled syringe as a new way to administer Lucentis to diabetic retinopathy patients.
The company’s drug is the only FDA-approved medicine indicated for the treatment of diabetic retinopathy. The 0.3-mg pre-filled syringe is the first device of its kind approved to deliver an anti-vascular endothelial growth factor agent to patients with diabetic retinopathy and diabetic macular edema.
Get the full story at our sister site, Drug Delivery Business News.
The post Genentech’s pre-filled syringe for diabetic retinopathy wins F...
Source: Mass Device - March 21, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat Genentech Roche Source Type: news
FDA Approves Genentech ’s Lucentis (ranibizumab injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy
South San Francisco, CA -- March 21, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the Lucentis (ranibizumab injection) 0.3 mg prefilled syringe... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 21, 2018 Category: Drugs & Pharmacology Source Type: news
893716 893716
Biomarkers from the anterior chamber of the eye help predict response to ranibizumab, which could spare patients repeated injections with an ineffective agent, a small trial suggested.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Biomarkers May Predict Rx Response in Diabetic Macular Edema Biomarkers May Predict Rx Response in Diabetic Macular Edema
Biomarkers from the anterior chamber of the eye help predict response to ranibizumab, which could spare patients repeated injections with an ineffective agent, a small trial suggested.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 9, 2018 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Repeated Ranibizumab Injections Safe in Diabetic Macular Edema Repeated Ranibizumab Injections Safe in Diabetic Macular Edema
In patients with diabetic macular edema, repeated ranibizumab injections are not associated with impaired macular perfusion and can be safely offered even to those with severe microangiopathy and advanced capillary dropout, researchers say.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 8, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Ranibizumab Safe, Effective for Macular Edema Due to Uncommon Causes Ranibizumab Safe, Effective for Macular Edema Due to Uncommon Causes
Ranibizumab 0.5 mg is safe and effective for patients with macular edema (ME) that is not due to diabetes, retinal vein occlusion (RVO) or neovascular age-related macular degeneration (nAMD), according to findings from the PROMETHEUS randomized trial.Reuters Health Information (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 28, 2018 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Anti-VEGF Agents Improve Vision Despite Ongoing Diabetic Macular Edema Anti-VEGF Agents Improve Vision Despite Ongoing Diabetic Macular Edema
In patients with diabetic macular edema (DME), aflibercept and ranibizumab are more effective than bevacizumab in preventing disease persistence, but each drug can lead to substantial gains in vision, according to a post hoc analysis of a randomized trial.Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 14, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Low-dose Ranibizumab Effective for Retinopathy of Prematurity Low-dose Ranibizumab Effective for Retinopathy of Prematurity
Low doses of anti-VEGF therapy with ranibizumab are effective in infants with retinopathy of prematurity (ROP), according to results from the CARE-ROP study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 9, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Ohr Pharmaceutical shares plummet after eye drug fails in wet-AMD trial
Shares in Ohr Pharmaceutical (NSDQ:OHRP) dropped -83% to trade at 35¢ apiece this morning after the company revealed that its topical therapy did not meet the primary endpoint of a trial evaluating its efficacy as a treatment for wet age-related macular degeneration.
The company’s Mako study randomized patients 1:1 to receive either Ohr’s topical, twice-daily squalamine therapy in combination with monthly Lucentis injections or a placebo combined with Lucentis.
Get the full story at our sister site, Drug Delivery Business News.
The post Ohr Pharmaceutical shares plummet after eye drug fails in wet-AMD trial ...
Source: Mass Device - January 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Wall Street Beat ohrpharmaceutical Source Type: news
Dexamethasone Does Not Improve Vision in Persistent Diabetic Macular Edema Dexamethasone Does Not Improve Vision in Persistent Diabetic Macular Edema
Adding dexamethasone to continued ranibizumab treatment reduces retinal thickness but does not improve vision in patients with persistent diabetic macular edema (DME), according to results from a phase 2 randomized trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news
Taxpayers pay twice for crucial drugs like Avastin | Letters
Big pharma companies are charging over the odds for medicines developed with public funding, writeHeidi Chow andTabitha HaIt is shocking, but not surprising, that big drugs companies are threatening to sue the NHS for using cheaper versions of drugs that could save people from going blind (Drug firms trying to stop cheap eye treatment on NHS, 1 November). Another part of this story is that the two medicines in question – Lucentis (known generically as ranibizumab) and Avastin (bevacizumab) are based on the groundbreaking discovery of monoclonal antibodies, whichwere developed with UK public funding.The NHS itself funded ...
Source: Guardian Unlimited Science - November 5, 2017 Category: Science Authors: Letters Tags: NHS Drugs Medical research Science Health Society Pharmaceuticals industry Business Blindness and visual impairment Disability Source Type: news
